See the following list to find out whether Descovy or ... also includes both drugs in its guidelines for HIV prevention. It’s important to note that your results from Descovy or Truvada may ...

It is given as a two-weekly injection or infusion, and it also needs to be taken in combination with other HIV medicines to work effectively. Pharmaceutical companies are researching other long-acting ...

Big Pharma is again raising the prices for key medications that could save the lives of millions in Georgia and there are still more hikes to come.

Conservative Christian business owners believe that covering HIV prevention medication violates their freedom of religion ...

Carl Schmid, executive director of the HIV+Hepatitis Policy Institute in Washington, D.C., talks about the problems associated with generic HIV PrEP drug markups and potential ways to fix it.

By Taylor Sisk for KFF Health News. Broadcast version by Nadia Ramlagan for West Virginia News Service reporting for the KFF ...

French biotech Abivax might be on the verge of HIV cure and prevention discovery, after achieving a significant reduction of viral load patients during the first 28 days of treatment.

The drug has already been green-lit in multiple countries for the treatment of adults with multi-drug resistant HIV in combination with other antiretrovirals. In a statement, Daniel O’Day ...

Dolutegravir is an HIV integrase strand transfer inhibitor (INSTI) that does not require pharmacokinetic boosting, has a long half-life allowing for once-daily dosing in treatment-naive patients ...

If access to the drugs is the bottleneck, stigma around HIV serves as a barrier stopping Black gay men and Black women from achieving the decline in HIV infections seen in white gay men.

The UN Development Programme (UNDP) has delivered 3000 antiretroviral drugs to Fiji to support the HIV response. The UNDP said Fiji is experiencing a concerning rise in new HIV cases. Last year, the ...

supporting its value in HIV ARV medication adherence studies (Nieuwkerk and Oort 2005; Simoni et al. 2006). An obstacle to progress in the HIV ARV medication adherence field has been the absence ...